Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's Oncomine Lung Cell-Free DNA Assay

Thermo Fisher Scientific has launched its Oncomine Lung Cell-Free DNA (cfDNA) assay. The assay is designed to target mutations in non-small cell lung cancer samples derived from circulating cfDNA in blood. It contains gene targets, such as EGFR and KRAS, and enables analysis with as little as one nanogram of initial sample or samples collected over time from the same subject. The Oncomine Lung cfDNA assay shows 90 percent sensitivity and more than 98 percent specificity at 0.1 percent limit of detection, the company said.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.